A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
about
Hepatitis A immunisation in persons not previously exposed to hepatitis AImmunoglobulins for preventing hepatitis AThe Cys-rich region of hepatitis A virus cellular receptor 1 is required for binding of hepatitis A virus and protective monoclonal antibody 190/4Live attenuated hepatitis A vaccines developed in ChinaViral hepatitis and the surgeonReport of the Workgroup on Viral DiseasesInhibitor-Based Therapeutics for Treatment of Viral HepatitisCohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based studyViral hepatitis.Antiinfectives update: focus on treatment and prevention of viral and associated infections.Control of hepatitis A infection in the U.S.Characterization of replication-competent hepatitis A virus constructs containing insertions at the N terminus of the polyproteinHepatitis A: old and new.Active immunization in the United States: developments over the past decade.Asian perspectives on viral hepatitis A.Hepatitis A vaccination.Safety and effectiveness of the new inactivated hepatitis A virus vaccine.Travel vaccines and elderly persons: review of vaccines available in the United States.A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses.Evolutionary origins of hepatitis A virus in small mammals.Proving non-inferiority or equivalence of two treatments with dichotomous endpoints using exact methods.Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use.Prevention of hepatitis A by vaccination.Hepatitis A vaccination during an outbreak among gay men in Montréal, Canada, 1995-1997.Hepatitis A virus infection: Is it an important hazard to public health?: hazards of HAV for public health.Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.Fever after immunization: current concepts and improved future scientific understanding.Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic reviewPrevention of hepatitis A by Havrix: a review.Hepatitis A infection during pregnancyNew developments in hepatitis A controlAttenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells.Vaccination against hepatitis A in children: A review of the evidence.Hepatitis A vaccination in developing countries: Is Syria next?Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.A simple and rapid Hepatitis A Virus (HAV) titration assay based on antibiotic resistance of infected cells: evaluation of the HAV neutralization potency of human immune globulin preparations.Seroepidemiology of hepatitis A virus in KuwaitVaccine-preventable infections in Systemic Lupus Erythematosus.Evaluation of hepatitis A vaccine in post-exposure prophylaxis, The Netherlands, 2004-2012.
P2860
Q24202104-8BA84849-0B30-4F32-AC3C-F0222EF28952Q24241613-F4C35EAF-0750-4BA8-9624-4DFF632407A6Q24523091-3994DFE3-D3E8-4007-9D6A-51176A4E56CFQ26866356-97D5E663-B12F-450D-9435-1B10274620B6Q27481282-5890FA25-1478-48CA-B304-2358B2D2114AQ27485870-0653B85F-C28D-4989-88EF-D08CB5713B5BQ28073697-6EA7724D-D0AB-4D06-8694-82F3B9A05240Q33265523-5860A62C-CDBD-4EF9-AC0E-7A049A44BEC4Q33289925-C1595AA2-84A2-468F-94FE-765C4104453FQ33624566-7B7F5C36-3B60-4619-A88F-0F07AC98E978Q33659379-A737D8C2-A35B-4D44-9A9D-AA2486FB46CFQ33708925-29135173-7618-4A57-BE90-382DEC1E406CQ33781995-173FE586-1573-44E1-A7EA-589EE2EAA87AQ33930596-9F913CBE-6C61-4D49-B502-6A252DF6422AQ33975799-BA08DDFF-130D-4550-990D-1B9CDC83CEE1Q34095726-B4C43DAB-0E48-42A9-AB9B-DFD126554815Q34210171-AFF6C517-2585-4A34-9901-21B3378FACD2Q34278232-E43FD4CF-DC17-4D9D-AF80-62D04498A633Q34392982-CE583BA0-CAE8-4353-A57D-ED723CB135C8Q34427768-314E1299-5E4F-4CFB-A71B-5DB1BD503569Q34501972-EB9B5263-AC1C-4755-BA8C-AE668AA763C0Q35078207-2D6DB9A4-434B-41CB-A82C-701AB9D50170Q35195906-F75ABF00-9AF4-4867-8B94-D2E8717A715AQ35207528-EC761315-A7F9-4FB1-9E93-18D4A77FB894Q35404759-183A50F9-584B-4AB0-BDF2-E23D65FD15B4Q35507708-5895BA81-F9B4-44EC-A8DB-6C4841377229Q35818688-917B3B5D-5942-49AA-BEC0-3F76AAF9CE3CQ35861311-A1235307-C4F2-4E71-A31E-49AAE188D1A9Q36175752-4F2BC5BD-A6F2-4A52-BDCB-501E6C011C07Q36238689-6D8491E8-7B88-4C4C-8C17-BD538886CD2AQ36274664-49EB8357-7E8D-49F7-9719-46F1A20F5A29Q36284559-02D594D7-F759-48E9-8872-01FB3A63B19DQ36619138-7875D19A-289D-4CE0-BEFF-3820A2534C62Q36663673-8E0944D3-8A23-47AC-8D44-0765D81EF391Q36970157-FEEBEDF2-DE50-4B6A-99C2-8BB5565AB923Q36993991-DA188511-1D35-498F-8FA3-E3715D71EBBDQ37052237-CE932530-41DE-4044-A2C6-C4996E0A5DD1Q37122111-1966CDC1-1BEB-42D7-A2E6-F21882BEC2DFQ37135056-9B28011C-6087-4CDD-8E2C-EAD54C92CC91Q37233646-2A2BE8F5-89C2-4A80-BD7B-2228CCAC7927
P2860
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
description
im August 1992 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 1992
@uk
name
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@en
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@nl
type
label
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@en
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@nl
prefLabel
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@en
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@nl
P2093
P1476
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
@en
P2093
A Werzberger
G Calandra
P356
10.1056/NEJM199208133270702
P407
P577
1992-08-13T00:00:00Z